Gene therapies help lung cancer victims — but not if they aren’t tested
Large clinicial trials proved that early-term lung cancer patients with specific genetic markers can live significantly longer, post-surgery, if they receive medical therapies based on their genetic signatures. Research by a local team based at Baptist Cancer Center and the University of Memphis School of Public Health shows that 40%, or two of out every five patients locally, did not get the testing. (The Daily Memphian file)
In the Mid-South, 40% of patients aren’t tested because doctors and hospitals aren’t on board, according to research in a national journal.
Topics
Dr. Raymond Osarogiagbon Matthew Smeltzer lung cancer Dr. Neil HayesJane Roberts
Jane Roberts has reported in Memphis for more than 20 years. As a senior member of The Daily Memphian staff, she was assigned to the medical beat during the COVID-19 pandemic. She also has done in-depth work on other medical issues facing our community, including shortages of specialists in local hospitals. She covered K-12 education here for years and later the region’s transportation sector, including Memphis International Airport and FedEx Corp.
Comments
Want to comment on our stories? If you’re a subscriber, scroll down to the comments. If you’re not a subscriber, only paid subscribers can add their thoughts, so subscribe now. Our commenting policy can be viewed here.